Dajun H. Yang
218 Xinghu Street
Suzhou, China
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Discovery of an Indole-Based p53-Y220C Reactivator with In Vivo Antitumor Activity via Structure-Guided Design.
Journal: Journal of medicinal chemistry
Published: June 10, 2026
BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.
Journal: Journal for immunotherapy of cancer
Published: June 03, 2026
Effects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia.
Journal: Clinical and translational science
Published: November 24, 2025
Phase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.
Journal: Clinical lymphoma, myeloma & leukemia
Published: November 10, 2025
Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma.
Journal: NPJ precision oncology
Published: July 17, 2025
A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer.
Journal: Cell reports. Medicine
Published: April 17, 2025
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
Journal: Med (New York, N.Y.)
Published: April 16, 2025
CYP4F11 promotes lung cancer progression through the miR-195/ME2 pathway.
Journal: Frontiers of medicine
Published: April 01, 2025
Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research.
Journal: Signal transduction and targeted therapy
Published: December 28, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Journal: JAMA oncology
Published: November 21, 2024
Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.
Journal: Clinical and translational science
Published: April 25, 2024
Last Updated: 09/26/2026